hydrochlorothiazide has been researched along with Diabetic Nephropathies in 36 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In summary, among patients with DKD, amiloride could decrease albuminuria without severe side effects, which was accompanied by the significant decline of urinary suPAR." | 9.41 | The effect of amiloride in decreasing albuminuria in patients with diabetic kidney diseases: a prospective, crossover, open-label study. ( Chen, Y; Dong, W; Huang, Y; Li, R; Li, Z; Liang, H; Liang, X; Liu, S; Ma, J; Shi, W; Wang, W; Wu, Y; Xie, Z; Ye, Z; Zhang, L; Zhao, X, 2021) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 8.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| "To define the importance of renal prostaglandins in nephrogenic diabetes insipidus (NDI), diuresis and the urinary excretion of PGE2 and PGF2 alpha were studied in a patient with NDI before and during inhibition of endogenous prostaglandin synthesis with either indomethacin (IND) or acetyl-salicylic acid (ASA)." | 7.67 | Comparative therapeutic benefit of indomethacin, hydrochlorothiazide, and acetyl-salicylic acid in a patient with nephrogenic diabetes insipidus. ( Favre, L; Jörg, J; Vallotton, MB; Vierhapper, H; Waldhäusl, W, 1984) |
| "Hydrochlorothiazide was then added for the subsequent 4 months." | 6.69 | Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. ( Half-Onn, E; Levi, Z; Rachmani, R; Ravid, M; Slavachevsky, I, 1998) |
| "Arterial hypertension is an independent risk factor for cardiovascular diseases and one of the major causes for mortality worldwide." | 6.45 | Rational of the use of aliskiren in hypertension and beyond. ( Savvatis, K; Schultheiss, HP; Tschöpe, C; Westermann, D, 2009) |
| "In summary, among patients with DKD, amiloride could decrease albuminuria without severe side effects, which was accompanied by the significant decline of urinary suPAR." | 5.41 | The effect of amiloride in decreasing albuminuria in patients with diabetic kidney diseases: a prospective, crossover, open-label study. ( Chen, Y; Dong, W; Huang, Y; Li, R; Li, Z; Liang, H; Liang, X; Liu, S; Ma, J; Shi, W; Wang, W; Wu, Y; Xie, Z; Ye, Z; Zhang, L; Zhao, X, 2021) |
| "We performed a post hoc analysis of 1) a prospective saline infusion study with 12 patients with arterial hypertension who received 2 L of isotonic saline over 4 hours, and 2) a randomized controlled trial with 45 diabetic nephropathy (DN) patients on background angiotensin-converting enzyme -inhibition (ACEi), who underwent 4 6-week treatment periods with add-on hydrochlorothiazide (HCT) or placebo, combined with regular sodium (RS) or low sodium (LS) diet in a cross-over design." | 5.22 | Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. ( de Borst, MH; Fliser, D; Heine, GH; Humalda, JK; Kwakernaak, AJ; Navis, G; Seiler-Muler, S; Vervloet, MG, 2016) |
| " A new clinical trial, GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension), is designed to compare the change in urinary albumin to creatinine ratio after 1 year of initial treatment with either amlodipine besylate/benazepril HCl or benazepril HCl/hydrochlorothiazide." | 5.11 | Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. ( Bakris, GL; McCullough, PA; Toto, RD, 2005) |
| " Inclusion criteria were type 2 diabetes, hypertension > 140/90 mmHg and current treatment with irbesartan or irbesartan/hydrochlorothiazide (HTCZ)." | 5.11 | [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ]. ( Krekler, M; Schmieder, RE, 2005) |
| "5 mg of hydrochlorothiazide, in 90 type 2 diabetic patients with microalbuminuria and blood pressure > 130/85 mmHg, receiving losartan 50 mg as initial treatment during 4 weeks." | 5.10 | Losartan titration versus diuretic combination in type 2 diabetic patients. ( de Pablos-Velasco, PL; Esmatjes, JE; Fernandez-Vega, F; Lopez de la Torre, ML; Pazos Toral, F; Pozuelo, A; Ruilope, LM, 2002) |
| "The objectives of this study were to compare the effects of the angiotensin II receptor blocker, losartan, to those of the angiotensin-converting enzyme inhibitor, enalapril, on albuminuria and renal function in relationship to clinic and ambulatory blood pressure (ABP) in hypertensive type 2 diabetic subjects with early nephropathy." | 5.09 | Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. ( Bélanger, A; Godin, C; Hallé, JP; Lacourcière, Y; Marion, J; Ross, S; Wright, N, 2000) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 4.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| " The aim of this study was to compare the effects of an equivalent reduction in blood pressure produced by the angiotensin-converting enzyme (ACE) inhibitor spirapril (SPI) and an antihypertensive triple drug combination of hydralazine, reserpine and hydrochlorothiazide (HRH) on kidney function, proteinuria and renal structure in hypertensive diabetic rats." | 3.70 | Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats. ( Armini, L; Bardelli, M; Calci, M; Campanacci, L; Candido, R; Carretta, R; Fabris, B; Fazio, M; Fischetti, F, 1999) |
| "To define the importance of renal prostaglandins in nephrogenic diabetes insipidus (NDI), diuresis and the urinary excretion of PGE2 and PGF2 alpha were studied in a patient with NDI before and during inhibition of endogenous prostaglandin synthesis with either indomethacin (IND) or acetyl-salicylic acid (ASA)." | 3.67 | Comparative therapeutic benefit of indomethacin, hydrochlorothiazide, and acetyl-salicylic acid in a patient with nephrogenic diabetes insipidus. ( Favre, L; Jörg, J; Vallotton, MB; Vierhapper, H; Waldhäusl, W, 1984) |
| "However, the effects of BDNF on diabetic nephropathy are unknown." | 2.80 | Assessment of glomerular filtration rate based on alterations of serum brain-derived neurotrophic factor in type 2 diabetic subjects treated with amlodipine/benazepril or valsartan/hydrochlorothiazide. ( Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2015) |
| "Seventy-six patients with type 2 diabetes and DKD (all with albuminuria and serum creatinine <1." | 2.78 | Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria. ( Gnudi, L; Hill, B; Karalliedde, J; Maltese, G; Viberti, G, 2013) |
| "Amlodipine and ramipril were added to their previous antihypertensive treatment for 12 weeks." | 2.72 | Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy. ( Bertoluci, MC; Oliveira, FR; Schmid, H; Schmidt, A; Thomazelli, FC; Uebel, D, 2006) |
| "Hydrochlorothiazide was then added for the subsequent 4 months." | 2.69 | Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. ( Half-Onn, E; Levi, Z; Rachmani, R; Ravid, M; Slavachevsky, I, 1998) |
| "Irbesartan reduces left ventricular hypertrophy and increases probability of maintenance of sinus rhythm after cardioversion of atrial fibrillation." | 2.48 | [Irbesartan in clinical practice]. ( Malishevskiĭ, MV, 2012) |
| "Arterial hypertension is an independent risk factor for cardiovascular diseases and one of the major causes for mortality worldwide." | 2.45 | Rational of the use of aliskiren in hypertension and beyond. ( Savvatis, K; Schultheiss, HP; Tschöpe, C; Westermann, D, 2009) |
| "Type 2 diabetic kidney disease (DKD) is frequently accompanied by uncontrollable hypertension due to the sodium sensitivity inherent in DKD and to diuretic-resistant edema." | 1.42 | Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease. ( Hirai, K; Hoshino, T; Ito, K; Kaku, Y; Miyazawa, H; Mori, H; Ookawara, S; Tabei, K; Ueda, Y; Yoshida, I, 2015) |
| "We describe a patient with diabetic nephropathy and proteinuria who developed a remarkable hyperkalaemia on treatment with an angiotensin-receptor blocker." | 1.34 | Treating proteinuria in a diabetic patient despite hyperkalaemia due to hyporeninaemic hypoaldosteronism. ( Bolk, JH; Ijpelaar, DH; van Nieuwkoop, C, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (16.67) | 18.7374 |
| 1990's | 7 (19.44) | 18.2507 |
| 2000's | 13 (36.11) | 29.6817 |
| 2010's | 9 (25.00) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Li, R | 1 |
| Xie, Z | 1 |
| Zhang, L | 1 |
| Huang, Y | 1 |
| Ma, J | 1 |
| Dong, W | 1 |
| Li, Z | 1 |
| Chen, Y | 1 |
| Liang, H | 1 |
| Wu, Y | 1 |
| Zhao, X | 1 |
| Wang, W | 1 |
| Ye, Z | 1 |
| Liu, S | 1 |
| Shi, W | 1 |
| Liang, X | 1 |
| Karalliedde, J | 1 |
| Maltese, G | 1 |
| Hill, B | 1 |
| Viberti, G | 1 |
| Gnudi, L | 1 |
| Hoshino, T | 1 |
| Ookawara, S | 1 |
| Miyazawa, H | 1 |
| Ito, K | 1 |
| Ueda, Y | 1 |
| Kaku, Y | 1 |
| Hirai, K | 1 |
| Mori, H | 1 |
| Yoshida, I | 1 |
| Tabei, K | 1 |
| Gangadhariah, MH | 1 |
| Luther, JM | 1 |
| Garcia, V | 1 |
| Paueksakon, P | 1 |
| Zhang, MZ | 2 |
| Hayward, SW | 1 |
| Love, HD | 1 |
| Falck, JR | 1 |
| Manthati, VL | 1 |
| Imig, JD | 1 |
| Schwartzman, ML | 1 |
| Zent, R | 1 |
| Capdevila, JH | 1 |
| Pozzi, A | 1 |
| Lee, IT | 1 |
| Sheu, WH | 1 |
| Hung, YJ | 1 |
| Chen, JF | 1 |
| Wang, CY | 1 |
| Lee, WJ | 1 |
| Humalda, JK | 1 |
| Seiler-Muler, S | 1 |
| Kwakernaak, AJ | 1 |
| Vervloet, MG | 1 |
| Navis, G | 1 |
| Fliser, D | 1 |
| Heine, GH | 1 |
| de Borst, MH | 1 |
| Westermann, D | 1 |
| Savvatis, K | 1 |
| Schultheiss, HP | 1 |
| Tschöpe, C | 1 |
| Kujal, P | 1 |
| Chábová, VČ | 1 |
| Vernerová, Z | 1 |
| Walkowska, A | 1 |
| Kompanowska-Jezierska, E | 1 |
| Sadowski, J | 1 |
| Vaňourková, Z | 1 |
| Husková, Z | 1 |
| Opočenský, M | 1 |
| Skaroupková, P | 1 |
| Schejbalová, S | 1 |
| Kramer, HJ | 1 |
| Rakušan, D | 1 |
| Malý, J | 1 |
| Netuka, I | 1 |
| Vaněčková, I | 1 |
| Kopkan, L | 1 |
| Cervenka, L | 1 |
| Kuriyama, S | 1 |
| Otsuka, Y | 1 |
| Ueda, H | 1 |
| Sugano, N | 1 |
| Yoshizawa, T | 1 |
| Yamada, T | 1 |
| Hosoya, T | 1 |
| Wang, S | 1 |
| Yang, S | 1 |
| Yang, H | 1 |
| Fan, X | 1 |
| Takahashi, T | 1 |
| Harris, RC | 1 |
| Malishevskiĭ, MV | 1 |
| Sidorenko, BA | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Stetsenko, TM | 1 |
| Tarykina, EV | 1 |
| Tsurko, VV | 1 |
| Bakris, GL | 2 |
| Toto, RD | 2 |
| McCullough, PA | 2 |
| Lehnert, H | 1 |
| Bramlage, P | 1 |
| Pittrow, D | 1 |
| Kirch, W | 1 |
| Schmieder, RE | 1 |
| Krekler, M | 1 |
| Bertoluci, MC | 1 |
| Uebel, D | 1 |
| Schmidt, A | 1 |
| Thomazelli, FC | 1 |
| Oliveira, FR | 1 |
| Schmid, H | 1 |
| Kamgar, M | 1 |
| Nobakhthaghighi, N | 1 |
| Shamshirsaz, AA | 1 |
| Estacio, RO | 1 |
| McFann, KK | 1 |
| Schrier, RW | 1 |
| van Nieuwkoop, C | 1 |
| Ijpelaar, DH | 1 |
| Bolk, JH | 1 |
| Joffe, HV | 1 |
| Kwong, RY | 1 |
| Gerhard-Herman, MD | 1 |
| Rice, C | 1 |
| Feldman, K | 1 |
| Adler, GK | 1 |
| Rocha, R | 1 |
| Purkayastha, D | 1 |
| Davis, P | 1 |
| Vierhapper, H | 1 |
| Jörg, J | 1 |
| Favre, L | 1 |
| Vallotton, MB | 1 |
| Waldhäusl, W | 1 |
| Andersen, O | 1 |
| Jacobsen, BB | 1 |
| Macleod, MD | 1 |
| Bell, GM | 1 |
| Irvine, WJ | 1 |
| Mahnensmith, RL | 1 |
| O'Brien, RC | 1 |
| Cooper, ME | 1 |
| Jerums, G | 1 |
| Doyle, AE | 1 |
| Tang, Z | 1 |
| Shou, I | 1 |
| Wang, LN | 1 |
| Fukui, M | 1 |
| Tomino, Y | 1 |
| Follansbee, MH | 1 |
| Beyer, KH | 1 |
| Griffith, JW | 1 |
| Vesell, ES | 1 |
| Man in't Veld, AJ | 1 |
| Rachmani, R | 1 |
| Levi, Z | 1 |
| Slavachevsky, I | 1 |
| Half-Onn, E | 1 |
| Ravid, M | 1 |
| Fabris, B | 1 |
| Candido, R | 1 |
| Armini, L | 1 |
| Fischetti, F | 1 |
| Calci, M | 1 |
| Bardelli, M | 1 |
| Fazio, M | 1 |
| Campanacci, L | 1 |
| Carretta, R | 1 |
| Lacourcière, Y | 1 |
| Bélanger, A | 1 |
| Godin, C | 1 |
| Hallé, JP | 1 |
| Ross, S | 1 |
| Wright, N | 1 |
| Marion, J | 1 |
| de Pablos-Velasco, PL | 1 |
| Pazos Toral, F | 1 |
| Esmatjes, JE | 1 |
| Fernandez-Vega, F | 1 |
| Lopez de la Torre, ML | 1 |
| Pozuelo, A | 1 |
| Ruilope, LM | 1 |
| Goicolea, I | 1 |
| Fernández González, R | 1 |
| Piniés, J | 1 |
| Garrido, J | 1 |
| Martínez, JM | 1 |
| Armenteros, S | 1 |
| Moreno Carretero, E | 1 |
| Anderson, S | 1 |
| Rennke, HG | 1 |
| Garcia, DL | 1 |
| Brenner, BM | 1 |
| Corman, LA | 1 |
| Skversky, NJ | 1 |
| Mioli, V | 1 |
| Zucchelli, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage[NCT04752293] | 125 participants (Anticipated) | Observational | 2021-05-19 | Recruiting | |||
| A 24-week Study to Evaluate the Effectiveness of Valsartan in Combination With Hydrochlorothiazide Versus Amlodipine on Arterial Compliance in Patients With Hypertension, Type 2 Diabetes and Albuminuria[NCT00171561] | Phase 4 | 144 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Evaluation of Hematologic Patients - Training Protocol[NCT00001715] | 898 participants (Actual) | Observational | 1998-04-21 | Completed | |||
| Aldosterone and Vascular Disease in Diabetes Mellitus[NCT00214825] | 46 participants (Actual) | Interventional | 2003-08-31 | Completed | |||
| An Evidence Base Study on the Clinical Effects of Integrated Western Medicine and Traditional Chinese Medicine for Diabetic Foot Ulcer Treatment[NCT00393510] | Phase 2 | 80 participants (Actual) | Interventional | 2000-11-30 | Completed | ||
| Delaying the Progression of Diabetic Nephropathy in Pima Indians[NCT00353600] | 25 participants (Anticipated) | Observational | 1994-08-19 | Completed | |||
| Renoprotection in Early Diabetic Nephropathy in Pima Indians[NCT00340678] | Phase 3 | 170 participants (Actual) | Interventional | 1995-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of successful limb rescued (without amputation). (NCT00393510)
Timeframe: 24 weeks
| Intervention | Participants (Number) |
|---|---|
| Traditional Chinese Medicine | 37 |
| Placebo | 31 |
Time taken for maturation of granulation to enable skin grafting. (NCT00393510)
Timeframe: 24 week
| Intervention | Weeks (Mean) |
|---|---|
| Traditional Chinese Medicine | 5.9 |
| Placebo | 9.2 |
The state of inflammation at baseline and at 4 weeks after treatment. TNF-alpha are in value of serum level. (NCT00393510)
Timeframe: Baseline and 4 week
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Baseline | Week 4 | |
| Placebo | 44 | 39 |
| Traditional Chinese Medicine | 48 | 28 |
(NCT00340678)
Timeframe: 6 years after first treatment
| Intervention | *10^6 cubic microns (Mean) |
|---|---|
| Normoalbuminuria Losartan | 5.4 |
| Normoalbuminuria Placebo | 5.6 |
| Microalbuminuria Losartan | 6.4 |
| Microalbuminuria Placebo | 7.0 |
Participants were monitored for up to 6 years. This is the number of participants who had a decline in GFR to less than or equal to 60 ml/min or to half the baseline value in subjects that enter the study with a GFR of less than 120 ml/min during the time of observation. (NCT00340678)
Timeframe: Up to 6 years
| Intervention | participants (Number) |
|---|---|
| Normoalbuminuria Losartan | 2 |
| Normoalbuminuria Placebo | 2 |
| Microalbuminuria Losartan | 1 |
| Microalbuminuria Placebo | 4 |
5 reviews available for hydrochlorothiazide and Diabetic Nephropathies
| Article | Year |
|---|---|
Rational of the use of aliskiren in hypertension and beyond.
Topics: Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl C | 2009 |
[Irbesartan in clinical practice].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2012 |
[Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl C | 2003 |
Diabetic nephropathy: a comprehensive approach.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Clinical Protocols; Clinical Tria | 1993 |
Clinical overview of irbesartan: expanding the therapeutic window in hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Contr | 1997 |
14 trials available for hydrochlorothiazide and Diabetic Nephropathies
| Article | Year |
|---|---|
The effect of amiloride in decreasing albuminuria in patients with diabetic kidney diseases: a prospective, crossover, open-label study.
Topics: Aged; Albuminuria; Amiloride; Creatinine; Cross-Over Studies; Diabetic Nephropathies; Drug Combinati | 2021 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Assessment of glomerular filtration rate based on alterations of serum brain-derived neurotrophic factor in type 2 diabetic subjects treated with amlodipine/benazepril or valsartan/hydrochlorothiazide.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Brain-Derived Neurotrophic Factor; Diabetes | 2015 |
Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy.
Topics: Aged; Cross-Over Studies; Diabetic Nephropathies; Diet, Sodium-Restricted; Diuretics; Double-Blind M | 2016 |
Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; A | 2005 |
[IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen | 2003 |
[Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compou | 2005 |
Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Gluco | 2006 |
Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Brachia | 2007 |
Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; A | 2008 |
Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; An | 1998 |
Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Neph | 2000 |
Losartan titration versus diuretic combination in type 2 diabetic patients.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Mellit | 2002 |
[Effect of antihypertensive combinations on arterial pressure, albuminuria, and glycemic control in patients with type II diabetic nephropathy: a randomized study].
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antih | 2002 |
17 other studies available for hydrochlorothiazide and Diabetic Nephropathies
| Article | Year |
|---|---|
Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabeti | 2015 |
Hypertension is a major contributor to 20-hydroxyeicosatetraenoic acid-mediated kidney injury in diabetic nephropathy.
Topics: Animals; Collagen; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 4; Diabetic Nephropathies; | 2015 |
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2010 |
Augmented antihypertensive effect of a fixed combination formula of candesartan and hydrochlorothiazide combined with furosemide in a patient on peritoneal dialysis.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Co | 2011 |
Role of blood pressure and the renin-angiotensin system in development of diabetic nephropathy (DN) in eNOS-/- db/db mice.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Captopri | 2012 |
Impaired fibrinolytic activity in type II diabetes: correlation with urinary albumin excretion and progression of renal disease.
Topics: Aged; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cohort Studies; Creat | 2006 |
Treating proteinuria in a diabetic patient despite hyperkalaemia due to hyporeninaemic hypoaldosteronism.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabet | 2007 |
Comparative therapeutic benefit of indomethacin, hydrochlorothiazide, and acetyl-salicylic acid in a patient with nephrogenic diabetes insipidus.
Topics: Adolescent; Aspirin; Diabetes Insipidus; Diabetic Nephropathies; Dinoprost; Dinoprostone; Diuresis; | 1984 |
The renin-aldosterone system in nephrogenic diabetes insipidus and the influence of hydrochlorothiazide and indomethacin.
Topics: Adolescent; Adult; Diabetes Insipidus; Diabetic Nephropathies; Drug Therapy, Combination; Female; Hu | 1983 |
Nephrogenic diabetes insipidus associated with Dyazide (triamterene-hydrochlorothiazide).
Topics: Aged; Angina Pectoris; Diabetes Insipidus; Diabetic Nephropathies; Diuretics; Drug Combinations; Hum | 1981 |
The effects of perindopril and triple therapy in a normotensive model of diabetic nephropathy.
Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressu | 1993 |
Effects of antihypertensive drugs or glycemic control on antioxidant enzyme activities in spontaneously hypertensive rats with diabetes.
Topics: Animals; Antihypertensive Agents; Antioxidants; Blood Glucose; Captopril; Catalase; Diabetes Mellitu | 1997 |
Studies on pyrazinoylguanidine. 5. Temporal effects over 24 weeks demonstrating attenuation of diabetic nephropathy in STZ-diabetic rats.
Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Ca | 1997 |
Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Diabetic | 1999 |
Short and long term effects of antihypertensive therapy in the diabetic rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Diabetic Nephropathies; Drug Administra | 1989 |
Short and long term effects of antihypertensive therapy in the diabetic rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Diabetic Nephropathies; Drug Administra | 1989 |
Short and long term effects of antihypertensive therapy in the diabetic rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Diabetic Nephropathies; Drug Administra | 1989 |
Short and long term effects of antihypertensive therapy in the diabetic rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Diabetic Nephropathies; Drug Administra | 1989 |
Methyldopa-hydrochlorothiazide therapy in hypertensive geriatric patients.
Topics: Aged; Blood Pressure; Coombs Test; Diabetic Nephropathies; Drug Combinations; Female; Hemoglobinomet | 1973 |
[The clinical use of an association of hydrochlorothiazide and triamterene in nephrotic syndromes].
Topics: Adolescent; Adult; Aged; Amyloidosis; Child; Diabetic Nephropathies; Diuresis; Electrolytes; Female; | 1966 |